Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson's disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:NTEC
- CUSIP: N/A
- Web: www.intecpharma.com
- Market Cap: $102.46 million
- Outstanding Shares: 13,738,000
- 50 Day Moving Avg: $7.75
- 200 Day Moving Avg: $7.75
- 52 Week Range: $4.20 - $9.05
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.22
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.57 per share
- Price / Book: 5.70
- Current Ratio: 6.40%
- Quick Ratio: 6.40%
- Average Volume: 82,643 shs.
- Beta: 1.31
- Short Ratio: 0.87
Frequently Asked Questions for Intec Pharma (NASDAQ:NTEC)
What is Intec Pharma's stock symbol?
Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."
How were Intec Pharma's earnings last quarter?
Intec Pharma Ltd. (NASDAQ:NTEC) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.09. View Intec Pharma's Earnings History.
When will Intec Pharma make its next earnings announcement?
Where is Intec Pharma's stock going? Where will Intec Pharma's stock price be in 2017?
4 brokerages have issued twelve-month price targets for Intec Pharma's stock. Their predictions range from $9.00 to $15.00. On average, they expect Intec Pharma's stock price to reach $12.25 in the next year. View Analyst Ratings for Intec Pharma.
What are analysts saying about Intec Pharma stock?
Here are some recent quotes from research analysts about Intec Pharma stock:
- 1. According to Zacks Investment Research, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson's disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. " (9/22/2017)
- 2. Maxim Group analysts commented, " As Intec initiates phase I trials of CBD/THC using the accordion delivery system, it opens up a new option for shareholders. The company extends the potential therapeutic utility of its proprietary delivery system beyond Parkinson's disease and insomnia. Cannabinoid-based therapeutics is a large, growing market, and as such, we look forward to any positive progress in this program which could be another value driver for the company." (3/24/2017)
Who are some of Intec Pharma's key competitors?
Some companies that are related to Intec Pharma include Zymeworks (ZYME), Cascadian Therapeutics (CASC), Spring Bank Pharmaceuticals (SBPH), vTv Therapeutics (VTVT), Aileron Therapeutics (ALRN), Verastem (VSTM), Threshold Pharmaceuticals (MTEM), Fate Therapeutics (FATE), Vascular Biogenics (VBLT), Cempra (CEMP), Recro Pharma (REPH), Conatus Pharmaceuticals (CNAT), Summit Therapeutics PLC (SMMT), ProQR Therapeutics N.V. (PRQR), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), AcelRx Pharmaceuticals (ACRX) and Aldeyra Therapeutics (ALDX).
Who are Intec Pharma's key executives?
Intec Pharma's management team includes the folowing people:
- John W. Kozarich, Chairman of the Board
- Jeffrey A. Meckler, Chief Executive Officer, Vice Chairman of the Board
- Nir Sassi, Chief Financial Officer
- Nadav Navon, Chief Operating Officer
- Liat Flaishon, Vice President-Clinical and Business Development
- Giora Carni, Director
When did Intec Pharma IPO?
(NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.
Who owns Intec Pharma stock?
Who bought Intec Pharma stock? Who is buying Intec Pharma stock?
How do I buy Intec Pharma stock?
Shares of Intec Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intec Pharma's stock price today?
MarketBeat Community Rating for Intec Pharma (NASDAQ NTEC)MarketBeat's community ratings are surveys of what our community members think about Intec Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Intec Pharma stock can currently be purchased for approximately $8.95.
Consensus Ratings for Intec Pharma (NASDAQ:NTEC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$12.25 (36.87% upside)|
Analysts' Ratings History for Intec Pharma (NASDAQ:NTEC)
(Data available from 9/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/21/2017||CIBC||Reiterated Rating||Outperform -> Outperform||$10.00 -> $15.00||Medium|
|9/21/2017||Oppenheimer Holdings, Inc.||Boost Price Target||Outperform||$10.00 -> $15.00||High|
|8/10/2017||Roth Capital||Set Price Target||Buy||$10.00||High|
|5/24/2017||Maxim Group||Set Price Target||Buy||$9.00||Low|
Earnings History for Intec Pharma (NASDAQ:NTEC)Earnings History by Quarter for Intec Pharma (NASDAQ NTEC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017|| || || || || || || || |
Earnings Estimates for Intec Pharma (NASDAQ:NTEC)
2017 EPS Consensus Estimate: ($1.28)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Intec Pharma (NASDAQ:NTEC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Intec Pharma (NASDAQ:NTEC)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Intec Pharma (NASDAQ:NTEC)
Latest Headlines for Intec Pharma (NASDAQ:NTEC)
Intec Pharma (NTEC) Chart for Sunday, September, 24, 2017